Evidence map›Paper›PMID 23185579›Full record

ArticlePloS one2012

Identification of small molecule inhibitors of PTPσ through an integrative virtual and biochemical approach.

Katie R Martin, Pooja Narang, Yong Xu, Audra L Kauffman, Joachim Petit, H Eric Xu, Nathalie Meurice, Jeffrey P MacKeigan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Katie R MartinLaboratory of Systems Biology, Van Andel Research Institute, Grand Rapids, Michigan, United States of America.
Pooja Narang
Yong Xu
Audra L Kauffman
Joachim Petit
H Eric Xu
Nathalie Meurice
Jeffrey P MacKeigan
Van Andel Institute · USMayo Clinic in Arizona · USMichigan United · US

Funding

The Southwest Comprehensive Center for Drug Discovery and DevelopmentRC2MH090878 · NIMH · TRANSLATIONAL GENOMICS RESEARCH INST · PI BERENS, MICHAEL E., HULME, CHRISTOPHER · 2009 to 2010
$7.6M
MK-STYX: A Requisite Gatekeeper to Mitochondrial Function and DeathR01CA138651 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI MACKEIGAN, JEFFREY PAUL · 2009 to 2013
$1.7M
NCI NIH HHS PC081089NCI NIH HHS R01 CA138651NCI NIH HHS R01CA138651NIMH NIH HHS RC2 MH090878
6 · The paper itself

Abstract

PTPσ is a dual-domain receptor type protein tyrosine phosphatase (PTP) with physiologically important functions which render this enzyme an attractive biological target. Specifically, loss of PTPσ has been shown to elicit a number of cellular phenotypes including enhanced nerve regeneration following spinal cord injury (SCI), chemoresistance in cultured cancer cells, and hyperactive autophagy, a process critical to cell survival and the clearance of pathological aggregates in neurodegenerative diseases. Owing to these functions, modulation of PTPσ may provide therapeutic value in a variety of contexts. Furthermore, a small molecule inhibitor would provide utility in discerning the cellular functions and substrates of PTPσ. To develop such molecules, we combined in silico modeling with in vitro phosphatase assays to identify compounds which effectively inhibit the enzymatic activity of PTPσ. Importantly, we observed that PTPσ inhibition was frequently mediated by oxidative species generated by compounds in solution, and we further optimized screening conditions to eliminate this effect. We identified a compound that inhibits PTPσ with an IC(50) of 10 µM in a manner that is primarily oxidation-independent. This compound favorably binds the D1 active site of PTPσ in silico, suggesting it functions as a competitive inhibitor. This compound will serve as a scaffold structure for future studies designed to build selectivity for PTPσ over related PTPs.

Indexed as

Molecular Docking SimulationDatabases, ProteinDrug DiscoveryEnzyme AssaysEnzyme InhibitorsHigh-Throughput Screening AssaysHumansOxidation-ReductionReceptor-Like Protein Tyrosine Phosphatases, Class 2Small Molecule LibrariesEnzyme InhibitorsReceptor-Like Protein Tyrosine Phosphatases, Class 2Small Molecule Libraries

Identifiers

PMID23185579
PMCPMC3502291
OpenAlexW2025662565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.